Deerfield Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Deerfield Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,722,241	Closed	-$11.3M	–	79
2019 Q3	$11.3M	Hold	2,722,241	–	–	0.46%	57
2019 Q2	$7.87M	Hold	2,722,241	–	–	0.28%	77
2019 Q1	$3.92M	Hold	2,722,241	–	–	0.15%	77
2018 Q4	$7.02M	Hold	2,722,241	–	–	0.28%	72
2018 Q3	$12M	Hold	2,722,241	–	–	0.43%	65
2018 Q2	$16.7M	Sell	2,722,241 -1,066,299	-28%	-$7.48M	0.59%	64
2018 Q1	$27.6M	Sell	3,788,540 -166,954	-4%	-$1.47M	0.96%	39
2017 Q4	$32.4M	Buy	3,955,494 +300,000	+8%	+$2.81M	1.28%	28
2017 Q3	$38.4M	Hold	3,655,494	–	–	1.73%	17
2017 Q2	$40.3M	Sell	3,655,494 -417,315	-10%	-$4.19M	2.15%	13
2017 Q1	$39.4M	Hold	4,072,809	–	–	1.52%	19
2016 Q4	$42.3M	Hold	4,072,809	–	–	1.74%	18
2016 Q3	$50.5M	Hold	4,072,809	–	–	2.35%	16
2016 Q2	$43.7M	Hold	4,072,809	–	–	1.72%	19
2016 Q1	$45M	Hold	4,072,809	–	–	1.91%	18
2015 Q4	$49.7M	Hold	4,072,809	–	–	2.02%	12
2015 Q3	$66.4M	Hold	4,072,809	–	–	2.57%	6
2015 Q2	$86.3M	Hold	4,072,809	–	–	2.88%	3
2015 Q1	$73.2M	Sell	4,072,809 -1,185,666	-23%	-$18.6M	2.37%	10
2014 Q4	$90.1M	Hold	5,258,475	–	–	3.24%	5
2014 Q3	$75.2M	Hold	5,258,475	–	–	2.74%	5
2014 Q2	$78.9M	Hold	5,258,475	–	–	3.17%	4
2014 Q1	$70.5M	Buy	5,258,475 +925,000	+21%	+$9.91M	2.88%	3
2013 Q4	$34.9M	Hold	4,333,475	–	–	1.81%	17
2013 Q3	$28.4M	Hold	4,333,475	–	–	1.32%	29
2013 Q2	$26.6M	Buy	+4,333,475	New	+$22.4M	1.25%	33

Other funds holding AVDL

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management's AVDL Position: Q4 2019 in Review

Deerfield Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2019, closing a stake of 2,722,241 shares — an estimated $11.3M sold.

Deerfield Management first reported a position in AVDL in Q2 2013 and held it in 26 quarters. The position peaked at $90.1M in Q4 2014. 42 funds tracked by Wall St. Rank hold AVDL as of Q4 2019.

Deerfield Management reported no remaining Avadel Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Deerfield Management sold 2,722,241 Avadel Pharmaceuticals shares in Q4 2019, an estimated $11.3M.
Deerfield Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 26 quarters.
Deerfield Management's Avadel Pharmaceuticals position peaked at $90.1M in Q4 2014.
42 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.